330792-70-6

Basic information

• Product Name: 5-aMino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile
• Synonyms: 5-aMino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile;3-AMino-4-cyano-5-(4-phenoxyphenyl)pyrazole;1H-Pyrazole-4-carbonitrile, 3-aMino-5-(4-phenoxyphenyl)-;3-amino-5-(4-phenoxyphenyl)-1H-Pyrazole-4-carbonitrile
• CAS NO: 330792-70-6
• Molecular Formula: C₁₆H₁₂N₄O
• Molecular Weight: 276.29268
• Mol File: 330792-70-6.mol
• Article Data: 26

Chemical Properties

• Boiling Point: 585.3±50.0 °C(Predicted)
• Appearance: /
• Density: 1.37±0.1 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 10.83±0.50(Predicted)
• CAS DataBase Reference: 5-aMino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 5-aMino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile(330792-70-6)
• EPA Substance Registry System: 5-aMino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile(330792-70-6)

Safety Data

• Hazardous Substances Data: 330792-70-6(Hazardous Substances Data)

Usage

Uses

3-Amino-4-cyano-5-(4-phenoxyphenyl)pyrazole has been used as a reactant in the preparation of ring-fused pyrazole derivatives to be used a inhibitors of lymphocyte-specific kinase (Lck)

Upstream product

• 330792-69-3 2-[(4-phenoxy-phenyl)-methoxy-methylene]-malononitrile 
• 109-77-3 malononitrile 
• 1055710-57-0 2-[amino(4-phenoxyphenyl)methylene]malononitrile 
• 108-95-2 phenol 
• 619-44-3 methyl 4-iodobenzoate 
• 330792-68-2 2-[hydroxy-(4-phenoxy-phenyl)-methylene]-malononitrile 
• 1623-95-6 4-phenoxybenzoyl chloride 
• 2215-77-2 4-Phenoxybenzoic acid 
• 21218-94-0 methyl 4-phenoxybenzoate 

Downstream Products

• 928309-79-9 C₂₄H₁₉BrN₄O 
• 1207957-96-7 C₂₅H₂₁BrN₄O 
• 928309-83-5 C₂₅H₂₁BrN₄O₂ 
• 928309-86-8 C₂₅H₂₁BrN₄O₂ 
• 1558038-40-6 C₂₇H₂₉N₅O₃ 
• 1558038-41-7 C₂₂H₂₃N₅O₂ 
• 1558037-08-3 C₃₀H₃₄N₆O₄ 
• 1558036-72-8 C₂₆H₂₅N₅O₃ 
• 1558038-55-3 C₂₈H₃₃N₅O₄ 
• 1558037-28-7 C₂₆H₂₇N₅O₃ 
• 1558038-54-2 C₂₈H₃₁N₅O₃ 
• 1612774-50-1 (R)-tert-butyl 3-(5-amino-4-cyano-3-(4-phenoxyphenyl)-1H-pyrazol-1-yl)piperidine-1-carboxylate 
• 1612774-51-2 (R)-tert-butyl 3-(5-amino-4-carbamoyl-3-(4-phenoxyphenyl)-1H-pyrazol-1-yl)piperidine-1-carboxylate 
• 1612774-53-4 (R)-tert-butyl 3-(3-amino-4-cyano-5-(4-phenoxyphenyl)-1H-pyrazol-1-yl)piperidine-1-carboxylate 

Relevant articles and documents

Regioselective Synthesis of Highly Functionalized Pyrazoles from N-Tosylhydrazones

A regioselective synthesis of highly functionalized pyrazoles from N-tosylhydrazones was developed. The reaction was general for a wide range of substrates and demonstrated excellent tolerance to a variety of substituents, and the method has been successfully applied to the formal synthesis of ibrutinib.

Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor

Therapeutic combinations of a proteasome inhibitor and a Bruton's tyrosine kinase (BTK) inhibitor are described. In some embodiments, the invention provides pharmaceutical compositions comprising combinations of a proteasome inhibitor and a BTK inhibitor and methods of using the pharmaceutical compositions for treating a disease, in particular a cancer.

USE OF A COMBINATION COMPRISING A BTK INHIBITOR FOR TREATING CANCERS

A method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor or a targeted therapy agent. A pharmaceutical combination comprising a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor or a targeted therapy agent.